Biotech firm BlackLabBio has been spun out from the University College Dublin to commercialise engineered protein products.

The Ireland-based firm, which has launched with €500,000 ($690k) in support from the Science Foundation Ireland and government agency Enterprise Ireland, is targeting large biotech companies with its products, and is already working with Novartis and AstraZeneca. It is estimated the engineered protein products market will be worth $168m globally by 2017.

David O’Connell, founder at BlackLabBio, said: “We have developed a patented…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?